Scientific publications

Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha

Panizo C, Rifón J, Rodríguez-Wilhelmi P, Cuesta B, Rocha E.
Hematology Department, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain

Magazine: Acta Haematologica

Date: Jun 1, 1999

Hematología y Hemoterapia [SP]

Primary plasma cell leukemia (PCL) is a rare form of plasma cell neoplasm with a poor prognosis.

Conventional melphalan-based treatments have been most disappointing. We report the case of a 62-year-old man with a primary form of PCL treated with VAD combination achieving an objective response, and who received high-dose melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by interferon-alpha. During the remission time, lasting for 3 years, an infiltration by large granular lymphocytes (LGL) was noted in peripheral blood. However, when the number of LGL declined, a bone marrow relapse was observed.

The treatment for PCL and the possible role of these LGL on tumor cell control after autologous PBSC transplantation are discussed.

CITATION Acta Haematol. 1999;101(4):193-6

you maybe interested


The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra